These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38442452)

  • 1. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).
    Villacampa G; Pascual T; Brasó-Maristany F; Paré L; Martínez-Sáez O; Cortés J; Ciruelos E; Martin M; Conte P; Carey LA; Fernandez A; Harbeck N; Marín-Aguilera M; Vivancos A; Curigliano G; Villagrasa P; Parker JS; Perou CM; Prat A; Tolaney SM
    ESMO Open; 2024 Mar; 9(3):102388. PubMed ID: 38442452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
    Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
    EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
    Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Marín-Aguilera M; Brasó-Maristany F; Waks AG; Pascual T; Martínez-Sáez O; Vivancos A; Conte PF; Guarneri V; Vittoria Dieci M; Griguolo G; Cortés J; Llombart-Cussac A; Muñoz M; Vidal M; Adamo B; Wolff AC; DeMichele A; Villagrasa P; Parker JS; Perou CM; Fernandez-Martinez A; Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM
    Ann Oncol; 2023 Sep; 34(9):783-795. PubMed ID: 37302750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
    Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E; Paré L; Schettini F; Martínez D; Jares P; Griguolo G; Dieci MV; Cortés J; Llombart-Cussac A; Conte B; Marín-Aguilera M; Chic N; Puig-Butillé JA; Martínez A; Galván P; Tsai YH; González-Farré B; Mira A; Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM
    EBioMedicine; 2022 Jan; 75():103801. PubMed ID: 34990895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
    Waks AG; Ogayo ER; Paré L; Marín-Aguilera M; Brasó-Maristany F; Galván P; Castillo O; Martínez-Sáez O; Vivancos A; Villagrasa P; Villacampa G; Tarantino P; Desai N; Guerriero J; Metzger O; Tung NM; Krop IE; Parker JS; Perou CM; Prat A; Winer EP; Tolaney SM; Mittendorf EA
    JAMA Oncol; 2023 Jun; 9(6):835-840. PubMed ID: 37103927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
    Tarantino P; Tayob N; Villacampa G; Dang C; Yardley DA; Isakoff SJ; Valero V; Faggen M; Mulvey T; Bose R; Weckstein D; Wolff AC; Reeder-Hayes K; Rugo HS; Ramaswamy B; Zuckerman D; Hart L; Gadi VK; Constantine M; Cheng K; Garrett AM; Marcom PK; Albain K; DeFusco P; Tung N; Ardman B; Nanda R; Jankowitz RC; Rimawi M; Abramson V; Pohlmann PR; Van Poznak C; Forero-Torres A; Liu MC; Ruddy KJ; Waks AG; DeMeo M; Burstein HJ; Partridge AH; Dell'Orto P; Russo L; Krause E; Newhouse DJ; Kurt BB; Mittendorf EA; Schneider B; Prat A; Winer EP; Krop IE; Tolaney SM; ;
    J Clin Oncol; 2024 Nov; 42(31):3652-3665. PubMed ID: 38935923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
    Llombart-Cussac A; Pérez-García J; Brasó-Maristany F; Paré L; Villacampa G; Gion M; Schmid P; Colleoni M; Borrego MR; Galván P; Parker JS; Buckingham W; Perou CM; Villagrasa P; Guerrero JA; Sampayo-Cordero M; Mancino M; Prat A; Cortés J
    Clin Cancer Res; 2024 Sep; 30(18):4123-4130. PubMed ID: 38995291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey.
    Martínez-Sáez O; Cortés J; Ciruelos E; Marín-Aguilera M; González G; Paré L; Herrera A; Villagrasa-González P; Prat A; Martín M
    Clin Transl Oncol; 2024 Aug; 26(8):2060-2069. PubMed ID: 38653928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
    Marín-Aguilera M; Jares P; Sanfeliu E; Villacampa G; Hernández-Lllán E; Martínez-Puchol AI; Shankar S; González-Farré B; Waks AG; Brasó-Maristany F; Pardo F; Manning DK; Abery JA; Curaba J; Moon L; Gordon O; Galván P; Wachirakantapong P; Castillo O; Nee CM; Blasco P; Senevirathne TH; Sirenko V; Martínez-Sáez O; Aguirre A; Krop IE; Li Z; Spellman P; Metzger Filho O; Polyak K; Michaels P; Puig-Butillé JA; Vivancos A; Matito J; Buckingham W; Perou CM; Villagrasa-González P; Prat A; Parker JS; Paré L
    ESMO Open; 2024 Mar; 9(3):102903. PubMed ID: 38452436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
    Brasó-Maristany F; Griguolo G; Chic N; Pascual T; Paré L; Maues J; Galván P; Dieci MV; Miglietta F; Giarratano T; Martínez-Sáez O; Marín-Aguilera M; Schettini F; Conte B; Angelats L; Vidal M; Adamo B; Muñoz M; Sanfeliu E; González B; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A; Guarneri V
    J Natl Cancer Inst; 2023 Mar; 115(3):332-336. PubMed ID: 36576009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
    Tolaney SM; Tarantino P; Graham N; Tayob N; Parè L; Villacampa G; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Barroso-Sousa R; Villagrasa P; DeMeo M; DiLullo M; Zanudo JGT; Weiss J; Wagle N; Partridge AH; Waks AG; Hudis CA; Krop IE; Burstein HJ; Prat A; Winer EP
    Lancet Oncol; 2023 Mar; 24(3):273-285. PubMed ID: 36858723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
    Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Massarrah T; Jerez Y; Ayala de la Peña F; García-Sáenz JÁ; Moreno F; Rodríguez-Lescure Á; Malón-Giménez D; Ballesteros García AI; Marín-Aguilera M; Galván P; Brasó-Maristany F; Waks AG; Tolaney SM; Mittendorf EA; Vivancos A; Villagrasa P; Parker JS; Perou CM; Paré L; Villacampa G; Prat A; Martín M
    JAMA Oncol; 2023 Jun; 9(6):841-846. PubMed ID: 37103916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
    Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
    J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
    Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
    ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.
    Ma S; Zhou Y; Ma D; Qi X; Jiang J
    Am J Cancer Res; 2024; 14(9):4218-4235. PubMed ID: 39417184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.